BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25883221)

  • 21. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.
    Martin KJ; Patrick DR; Bissell MJ; Fournier MV
    PLoS One; 2008 Aug; 3(8):e2994. PubMed ID: 18714348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients.
    Sun J; Chen X; Wang Z; Guo M; Shi H; Wang X; Cheng L; Zhou M
    Sci Rep; 2015 Nov; 5():16553. PubMed ID: 26549855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A gene-expression signature as a predictor of survival in breast cancer.
    van de Vijver MJ; He YD; van't Veer LJ; Dai H; Hart AA; Voskuil DW; Schreiber GJ; Peterse JL; Roberts C; Marton MJ; Parrish M; Atsma D; Witteveen A; Glas A; Delahaye L; van der Velde T; Bartelink H; Rodenhuis S; Rutgers ET; Friend SH; Bernards R
    N Engl J Med; 2002 Dec; 347(25):1999-2009. PubMed ID: 12490681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer.
    Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Elger T; Krajnak S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
    Breast Cancer Res Treat; 2017 Sep; 165(2):293-300. PubMed ID: 28585074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm.
    Glinsky GV; Higashiyama T; Glinskii AB
    Clin Cancer Res; 2004 Apr; 10(7):2272-83. PubMed ID: 15073102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
    Cai H; Li X; Li J; Ao L; Yan H; Tong M; Guan Q; Li M; Guo Z
    Oncotarget; 2015 Dec; 6(42):44593-608. PubMed ID: 26527319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autophagy-related prognostic signature for breast cancer.
    Gu Y; Li P; Peng F; Zhang M; Zhang Y; Liang H; Zhao W; Qi L; Wang H; Wang C; Guo Z
    Mol Carcinog; 2016 Mar; 55(3):292-9. PubMed ID: 25620657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells.
    Daniels MW; Brock GN; Wittliff JL
    Breast Cancer Res Treat; 2017 Jan; 161(2):245-258. PubMed ID: 27858316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences.
    Speers C; Chang SL; Pesch A; Ritter C; Olsen E; Chandler B; Moubadder L; Liu M; Cameron M; Michmerhuizen A; Wilder-Romans K; Zhao SG; Nyati S; Bartelink H; Feng FY; Pierce LJ
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):686-696. PubMed ID: 32434041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy.
    Hellwig B; Madjar K; Edlund K; Marchan R; Cadenas C; Heimes AS; Almstedt K; Lebrecht A; Sicking I; Battista MJ; Micke P; Schmidt M; Hengstler JG; Rahnenführer J
    PLoS One; 2016; 11(12):e0167585. PubMed ID: 27926932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of triple-negative breast cancer radiosensitive gene signature and validation based on transcriptome analysis.
    Wushou A; Jiang YZ; Hou J; Liu YR; Guo XM; Shao ZM
    Breast Cancer Res Treat; 2015 Nov; 154(1):57-62. PubMed ID: 26476726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.
    Drukker CA; Elias SG; Nijenhuis MV; Wesseling J; Bartelink H; Elkhuizen P; Fowble B; Whitworth PW; Patel RR; de Snoo FA; van 't Veer LJ; Beitsch PD; Rutgers EJ
    Breast Cancer Res Treat; 2014 Dec; 148(3):599-613. PubMed ID: 25414025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Copy number profiling of Oncotype DX genes reveals association with survival of breast cancer patients.
    Ahmed W; Malik MFA; Saeed M; Haq F
    Mol Biol Rep; 2018 Dec; 45(6):2185-2192. PubMed ID: 30225582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A specific gene expression signature for visceral organ metastasis in breast cancer.
    Savci-Heijink CD; Halfwerk H; Koster J; Horlings HM; van de Vijver MJ
    BMC Cancer; 2019 Apr; 19(1):333. PubMed ID: 30961553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic stromal gene signatures in breast cancer.
    Winslow S; Leandersson K; Edsjö A; Larsson C
    Breast Cancer Res; 2015 Feb; 17(1):23. PubMed ID: 25848820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer--the INNODIAG study.
    Kempowsky-Hamon T; Valle C; Lacroix-Triki M; Hedjazi L; Trouilh L; Lamarre S; Labourdette D; Roger L; Mhamdi L; Dalenc F; Filleron T; Favre G; François JM; Le Lann MV; Anton-Leberre V
    BMC Med Genomics; 2015 Feb; 8():3. PubMed ID: 25888889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
    Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
    Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.